COCOON Baseline Characteristics
Panelists discuss how the baseline characteristics of patients in the COCOON trial were evenly matched, with slightly more women than men and a significant number of Asian patients, which is typical for EGFR-mutant non–small cell lung cancer.
Video content above is prompted by the following:
Baseline Characteristics of COCOON Study Population
Upon reviewing the baseline characteristics of the study population, both arms appear to be well-balanced overall, with no significant disparities that would affect the interpretation of treatment outcomes.
- The demographic distribution reflects a slightly higher proportion of female patients than male patients, which is consistent with the known epidemiology of EGFR-mutant non–small cell lung cancer (NSCLC). This subtype of lung cancer is more frequently observed in women.
- The average age of participants is in the early 60s, aligning with the typical age of diagnosis for EGFR-mutant NSCLC. Additionally, there is a notably high representation of Asian patients, which is expected given the increased prevalence of EGFR mutations among individuals of Asian descent, including both Asian Americans and those residing in Asia.
Overall, the baseline characteristics were consistent with what would be expected in a population with EGFR-mutant NSCLC and there were no surprising findings that would confound or bias the study’s comparative analysis between the treatment arms.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
